The Biokhimik pharmaceutical plant in Saransk, a member of the Promomed group, is set to make its mark in the Middle East markets following a successful audit conducted by the Iraqi Ministry of Health. The production site in Mordovia received high marks from foreign inspectors, said the head of Mordovia, Artem Zdunov.
Promomed’s management has announced that the newly acquired certificate will facilitate the export of a diverse array of sterile and non-sterile dosage forms to Iraq.The plans involve registering around 300 drug names in various forms and dosages, including treatments for neurological and oncological diseases, plus antibacterial and anti-inflammatory drugs.
